These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31203199)

  • 1. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.
    Komura N; Mabuchi S; Yokoi E; Shimura K; Kawano M; Matsumoto Y; Kimura T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1057-1063. PubMed ID: 31203199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer.
    Li Y; Zhang C; Ji R; Lu H; Zhang W; Li LL; Liu R; Qian H; He A
    Int J Gynecol Cancer; 2020 Jan; 30(1):74-82. PubMed ID: 31822507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
    Lee M; Kim SW; Nam EJ; Yim GW; Kim S; Kim YT
    Gynecol Oncol; 2011 Aug; 122(2):238-41. PubMed ID: 21531448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
    Zhou M; Li L; Wang X; Wang C; Wang D
    Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.
    Wang B; Wang S; Ren W
    BMC Cancer; 2021 May; 21(1):609. PubMed ID: 34034697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review.
    Komura N; Mabuchi S; Yokoi E; Kozasa K; Kuroda H; Sasano T; Matsumoto Y; Kimura T
    Int J Clin Oncol; 2018 Feb; 23(1):104-113. PubMed ID: 28951992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of thrombocytosis in ovarian cancer.
    Słabuszewska-Jóźwiak A; Dmoch-Gajzlerska E; Kozakiewicz B; Jakiel G
    Ann Agric Environ Med; 2015; 22(4):731-5. PubMed ID: 26706987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer.
    Ma X; Wang Y; Sheng H; Tian W; Qi Z; Teng F; Xue F
    J Obstet Gynaecol Res; 2014 Jan; 40(1):178-83. PubMed ID: 24102732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma.
    Hsieh SF; Lau HY; Wu HH; Hsu HC; Twu NF; Cheng WF
    Int J Environ Res Public Health; 2019 Feb; 16(4):. PubMed ID: 30795566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis.
    Ceran MU; Tasdemir U; Colak E; Güngör T
    J Ovarian Res; 2019 Feb; 12(1):16. PubMed ID: 30744662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
    Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
    Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
    Lydiksen L; Jensen-Fangel S; Blaakaer J
    Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.